{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T04:40:05Z","timestamp":1756528805966,"version":"3.44.0"},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,8,26]]},"DOI":"10.1248\/bpb.b25-00077","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T22:08:35Z","timestamp":1756159715000},"page":"1233-1238","source":"Crossref","is-referenced-by-count":0,"title":["&lt;i&gt;In Silico&lt;\/i&gt; Exploration of Therapeutics for GLP-1 Receptor Agonist-Induced Nausea and Their &lt;i&gt;in Vivo&lt;\/i&gt; Validation in Mice"],"prefix":"10.1248","volume":"48","author":[{"given":"Norihiro","family":"Shibui","sequence":"first","affiliation":[{"name":"Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46\u201329 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606\u20138501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46\u201329 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606\u20138501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46\u201329 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606\u20138501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46\u201329 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606\u20138501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46\u201329 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606\u20138501, Japan"},{"name":"Laboratory of Clinical Evidence-based Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyushu University, 3\u20131\u20131 Maidashi, Higashi-ku, Fukuoka 812\u20138582, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Faculty of Health Sciences, Morinomiya University of Medical Sciences, 1\u201326\u201316 Nanko-Kita, Suminoe-ku, Osaka 559\u20138611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nagayasu","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, 46\u201329 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606\u20138501, Japan"},{"name":"Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"},{"name":"Project for Neural Networks, Graduate School of Pharmaceutical Sciences, Osaka University, 1\u20136 Yamadaoka, Suita, Osaka 565\u20130871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Aroda VR, Rosenstock J, Terauchi Y, Jeppesen OLE, Christiansen E, Hertz CL, Haluzik M. Effect and safety of oral semaglutide monotherapy in type 2 diabetes\u2014Pioneer 1 trial. <i>Diabetes<\/i>, <b>67<\/b>(Supplement 1), 2\u2013LB (2018).","DOI":"10.2337\/db18-2-LB"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. <i>Drugs Context<\/i>, <b>4<\/b>, 212283 (2015).","DOI":"10.7573\/dic.212283"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes Obes. Metab.<\/i>, <b>18<\/b>, 203\u2013216 (2016).","DOI":"10.1111\/dom.12591"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. <i>Diabetes Metab. Syndr. Obes.<\/i>, <b>10<\/b>, 403\u2013412 (2017).","DOI":"10.2147\/DMSO.S141235"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Borner T, Tinsley IC, Doyle RP, Hayes MR, De Jonghe BC. Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting? <i>Br. J. Pharmacol.<\/i>, <b>179<\/b>, 542\u2013556 (2022).","DOI":"10.1111\/bph.15647"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, Gathright GR, Yates BJ, Andrews PLR. Why can\u2019t rodents vomit? A comparative behavioral, anatomical, and physiological study. <i>PLOS ONE<\/i>, <b>8<\/b>,  e60537 (2013).","DOI":"10.1371\/journal.pone.0060537"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Liu YL, Malik N, Sanger GJ, Friedman MI, Andrews PLR. Pica - A model of nausea? Species differences in response to cisplatin. <i>Physiol. Behav.<\/i>, <b>85<\/b>, 271\u2013277 (2005).","DOI":"10.1016\/j.physbeh.2005.04.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yamamoto K, Nakai M, Nohara K, Yamatodani A. The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential. <i>Eur. J. Pharmacol.<\/i>, <b>554<\/b>, 34\u201339 (2007).","DOI":"10.1016\/j.ejphar.2006.09.058"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Li Z, Zhang X, Zheng J, Huang M. Pica behavior induced by body rotation in mice. <i>ORL J. Otorhinolaryngol. Relat. Spec.<\/i>, <b>70<\/b>, 162\u2013167 (2008).","DOI":"10.1159\/000124289"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Takeda N, Morita M, Hasegawa S, Kubo T, Matsunaga T. Neurochemical mechanisms of motion sickness. <i>Am. J. Otolaryngol.<\/i>, <b>10<\/b>, 351\u2013359 (1989).","DOI":"10.1016\/0196-0709(89)90112-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yamamoto K, Nohara K, Furuya T, Yamatodani A. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. <i>Pharmacol. Biochem. Behav.<\/i>, <b>82<\/b>, 24\u201329 (2005).","DOI":"10.1016\/j.pbb.2005.07.007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, Zafar MU, Benard L, Badimon JJ, Hajjar RJ, Goldfarb J, Iyengar R. Systems pharmacology of adverse event mitigation by drug combinations. <i>Sci. Transl. Med.<\/i>, <b>5<\/b>, 206ra140 (2013).","DOI":"10.1126\/scitranslmed.3006548"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Nagashima T, Shirakawa H, Nakagawa T, Kaneko S. Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. <i>Sci. Rep.<\/i>, <b>6<\/b>, 26375 (2016).","DOI":"10.1038\/srep26375"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nagaoka K, Nagashima T, Asaoka N, Yamamoto H, Toda C, Kayanuma G, Siswanto S, Funahashi Y, Kuroda K, Kaibuchi K, Mori Y, Nagayasu K, Shirakawa H, Kaneko S. Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. <i>JCI Insight<\/i>, <b>6<\/b>,  e145632 (2021).","DOI":"10.1172\/jci.insight.145632"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Furuta H, Yamada M, Nagashima T, Matsuda S, Nagayasu K, Shirakawa H, Kaneko S. Increased expression of glutathione peroxidase 3 prevents tendinopathy by suppressing oxidative stress. <i>Front. Pharmacol.<\/i>, <b>14<\/b>, 1137952 (2023).","DOI":"10.3389\/fphar.2023.1137952"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Morita M, Takeda N, Kubo T, Matsunaga T. Pica as an index of motion sickness in rats. <i>ORL J. Otorhinolaryngol. Relat. Spec.<\/i>, <b>50<\/b>, 188\u2013192 (1988).","DOI":"10.1159\/000275989"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. <i>Cochrane Database Syst. Rev.<\/i>, <b>CD006103<\/b>, CD006103 (2010).","DOI":"10.1002\/14651858.CD006103.pub4"},{"key":"18","unstructured":"18) Del Rosso JQ, Kircik L. Oral apremilast for the treatment of plaque psoriasis. <i>J. Clin. Aesthet. Dermatol.<\/i>, <b>9<\/b>, 43\u201348 (2016)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Jones B, Buenaventura T, Kanda N, <i>et al<\/i>. Targeting GLP-1 receptor trafficking to improve agonist efficacy. <i>Nat. Commun.<\/i>, <b>9<\/b>, 1602 (2018).","DOI":"10.1038\/s41467-018-03941-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. <i>Therap. Adv. Gastroenterol.<\/i>, <b>9<\/b>, 98\u2013112 (2016).","DOI":"10.1177\/1756283X15618131"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. <i>J. Comp. Neurol.<\/i>, <b>403<\/b>, 261\u2013280 (1999).","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) \u00d8rskov C, Poulsen SS, M\u00f8ller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. <i>Diabetes<\/i>, <b>45<\/b>, 832\u2013835 (1996).","DOI":"10.2337\/diab.45.6.832"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Reiner DJ, Mietlicki-Baase EG, McGrath LE, Zimmer DJ, Bence KK, Sousa GL, Konanur VR, Krawczyk J, Burk DH, Kanoski SE, Hermann GE, Rogers RC, Hayes MR. Astrocytes regulate GLP-1 receptor-mediated effects on energy balance. <i>J. Neurosci.<\/i>, <b>36<\/b>, 3531\u20133540 (2016).","DOI":"10.1523\/JNEUROSCI.3579-15.2016"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Mietlicki-Baase EG, Liberini CG, Workinger JL, Bonaccorso RL, Borner T, Reiner DJ, Koch-Laskowski K, McGrath LE, Lhamo R, Stein LM, De Jonghe BC, Holz GG, Roth CL, Doyle RP, Hayes MR. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents. <i>Diabetes Obes. Metab.<\/i>, <b>20<\/b>, 1223\u20131234 (2018).","DOI":"10.1111\/dom.13222"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. <i>J. Neurol. Neurosurg. Psychiatry<\/i>, <b>50<\/b>, 682\u2013686 (1987).","DOI":"10.1136\/jnnp.50.6.682"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Dworkin RH, Backonja M, Rowbotham MC, <i>et al<\/i>. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. <i>Arch. Neurol.<\/i>, <b>60<\/b>, 1524\u20131534 (2003).","DOI":"10.1001\/archneur.60.11.1524"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T-Z, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>103<\/b>, 17537\u201317542 (2006).","DOI":"10.1073\/pnas.0409066103"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel alpha2-delta [Cavalpha2-delta] ligands. <i>Pain<\/i>, <b>142<\/b>, 13\u201316 (2009).","DOI":"10.1016\/j.pain.2008.11.019"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. <i>Lancet<\/i>, <b>361<\/b>, 1703\u20131705 (2003).","DOI":"10.1016\/S0140-6736(03)13365-X"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. <i>Endocrinology<\/i>, <b>146<\/b>, 3748\u20133756 (2005).","DOI":"10.1210\/en.2005-0473"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean MEJ, NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. <i>Lancet<\/i>, <b>374<\/b>, 1606\u20131616 (2009).","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Yamamoto K, Yamatodani A. Strain differences in the development of cisplatin-induced pica behavior in mice. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>91<\/b>, 66\u201371 (2018).","DOI":"10.1016\/j.vascn.2018.01.559"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide. <i>Drug Dev. Res.<\/i>, <b>53<\/b>, 260\u2013267 (2001).","DOI":"10.1002\/ddr.1195"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. <i>Gastroenterology<\/i>, <b>121<\/b>, 767\u2013774 (2001).","DOI":"10.1053\/gast.2001.28466"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, Breivogel CS. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. <i>Eur. J. Pharmacol.<\/i>, <b>459<\/b>, 83\u201395 (2003).","DOI":"10.1016\/S0014-2999(02)02815-7"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, Maione S, Rossi F, Giagnoni G. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. <i>Br. J. Pharmacol.<\/i>, <b>148<\/b>, 1022\u20131032 (2006).","DOI":"10.1038\/sj.bjp.0706798"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/8\/48_b25-00077\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T04:03:48Z","timestamp":1756526628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/8\/48_b25-00077\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00077","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"b25-00077"}}